



S/N 10/071,861

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Kevin M. Slawin et al.

Examiner: Unknown

Serial No.: 10/071,861

Group Art Unit: 1645

Filed: February 7, 2002

Docket: 675.002US1

Title: METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE  
CANCERRECEIVED  
JAN 28 2003  
TECH CENTER 1600/1600**INFORMATION DISCLOSURE STATEMENT**Assistant Commissioner for Patents  
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

The attached references were discovered in part as a result of an International Search Report in a related copending foreign patent application. Enclosed for the Examiner's information is a copy of the references and the International Search Report.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

KEVIN M. SLAWIN ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6959

Date

January 20, 2003

By

  
Janet E. Embretson  
Reg. No. 39,665

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 28<sup>th</sup> day of January, 2003.


Name

Mark J. Gambetta

Signature

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin M.D., Kevin
Group Art Unit	1645
Examiner Name	Unknown

Sheet 1 of 3

Attorney Docket No: 675.002US1

**RECEIVED**  
 JAN 28 2003  
 TECH CENTER 160012900

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-5,993,388	11/30/1999	Kattan, M. W., et al	600	300	06/25/1998
	US-6,409,664	06/25/2002	Kattan, M. W., et al	600	300	11/24/1999

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
	WO-00/63841	10/26/2000	Wilkinson, L.	G06T	11/00	
	WO-99/38011	07/29/1999	Pollack, M. N., et al	G01N	33/574	


**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		"Human IL- sR Immunoassay, For the quantitative determination of human Interleukin 6 soluble Receptor (IL-6 sR) concentrations in cell culture supernate, serum, plasma, and urine", <u>Quantikine</u> , Catalog Number DR600, pp. 1-15	
		"Human IL-6 Immunoassay, For the quantitative determination of human interleukin 6 (IL-6) concentrations in cell culture supernate, serum, and plasma", <u>Quantikine</u> , Catalog Number D6050, pp. 1-15	
		ADLER, H.L., et al., "Elevated Levels of Circulating Interleukin-6 and Transforming Growth Factor- $\beta$ 1 in Patients with Metastatic Prostatic Carcinoma", <u>The Journal of Urology</u> , 161, (January, 1999), pp. 182-187	
		AKIMOTO, S., et al., "Relationship Between Serum Levels of Interleukin-6, Tumor Necrosis Factor- $\alpha$ and Bone Turnover Markers in Prostate Cancer Patients", <u>Endocrine Journal</u> , Vol. 45, No. 2, (1998), pp. 183-189	
		BELLUCO, C., et al., "Interleukin-6 Blood Level Is Associated With Circulating Carcinoembryonic Antigen and Prognosis in Patients With Colorectal Cancer", <u>Annals of Surgical Oncology</u> , Vol. 7, No. 1, (March, 2000), pp. 133-138	
		FIGUEROA, J.A., et al., "Differential Expression of Insulin-Like Growth Factor Binding Proteins in High Versus Low Gleason Score Prostate Cancer", <u>The Journal of Urology</u> , 159, (April, 1998), pp. 1379-1383	
		IVANOVIC, V., et al., "Elevated plasma levels of TGF- $\beta$ 1 in patients with invasive prostate cancer", <u>Nature Medicine</u> , Vol. 1, No. 4, (April 4, 1995), pp. 282-283	
		JUNKER, U., et al., "Transforming Growth Factor Beta 1 is Significantly Elevated in Plasma of Patients Suffering From Renal Cell Carcinoma", <u>Cytokine</u> , Vol. 8, No. 10, (October, 1996), pp. 794-798	
		KAKEHI, Y., et al., "Serum TGF- $\beta$ 1 Levels in Patients with Prostatic Cancer: Positive Correlation with Metastasis and Inverse Correlation with Age", <u>Proceedings of the American Urological Association</u> , Vol. 155, abstract 435, (May, 1996), 1 page	

**EXAMINER****DATE CONSIDERED**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin M.D., Kevin
Group Art Unit	1645
Examiner Name	Unknown

Sheet 2 of 3

Attorney Docket No: 675.002US1

RECEIVED  
JAN 28 2003  
TECH CENTER 1600/2900

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KATTAN, M.W., et al., "A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer", <u>Journal of the National Cancer Institute</u> , Vol. 90, No. 10, (May 20, 1998), pp. 766-771	
		KONG, FENG-MING, et al., "Elevated Plasma Transforming Growth Factor- $\beta_1$ Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor", <u>Ann. Surg.</u> , Vol. 222, No. 2, (1995), pp. 155-162	
		KRASAGAKIS, K., et al., "Elevated plasma levels of transforming growth factor (TGF)- $\beta_1$ and TGF- $\beta_2$ in patients with desseminated malignant melanoma", <u>British Journal of Cancer</u> , Vol. 77, No. 9, (1998), pp. 1492-1494	
		LANGE, I., et al., "Plasma-TGF- $\beta_1$ -Konzentrationen bei Patienten mit einem Prostatakarzinom oder einer benignen Prostatahyperplasie", <u>Der Urologe</u> , Vol. 37, (1998), pp. 199-202	With English Abstract
		NAKASHIMA, J., et al., "Serum Interleukin 6 as a Prognostic Factor in Patients with Prostate Cancer", <u>Clinical Cancer Research</u> , 6, (July, 2000), pp. 2702-2706	
		PERRY, K.T., et al., "Transforming Growth Factor Beta as a Clinical Biomarker for Prostate Cancer", <u>Urology</u> , Vol. 49, No. 1, (1997), pp. 151-155	
		SCAMBIA, G., et al., "Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer", <u>British Journal of Cancer</u> , (1995), pp. 354-356	
		SHARIAT, S.F., et al., "Association of Preoperative Plasma Levels of Insulin-Like Growth Factor I and Insulin-Like Growth Factor Binding Proteins-2 and -3 with Prostate Cancer Invasion, Progression, and Metastasis", <u>Journal of Clinical Oncology</u> , 20, (February 1, 2002), pp. 833-841	
		SHARIAT, S.F., et al., "Plasma Levels of Interleukin-6 and Its Soluble Receptor are Associated with Prostate Cancer Progression and Metastasis", <u>Urology</u> , 58, (2001), pp. 1008-1015	
		SHARIAT, S.F., et al., "Preoperative Plasma Levels of Transforming Growth Factor $\beta_1$ (TGF- $\beta_1$ ) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy", <u>Journal of Clinical Oncology</u> , 19, (June 1, 2001), pp. 2856-2864	With Abstract
		SHIM, K.S., et al., "Elevated Serum Levels of Transforming Growth Factor- $\beta_1$ in Patients with Colorectal Carcinoma", <u>American Cancer Society</u> , (1999), pp. 554-561	
		SMITH, D.S., et al., "Longitudinal Screening for Prostate Cancer with Prostate-Specific Antigen", <u>JAMA</u> , Vol. 276, No. 16, (October, 1996), pp. 1309-1315	
		TSUSHIMA, H., et al., "High Levels of Transforming Growth Factor $\beta_1$ in Patients With Colorectal Cancer: Association With Disease Progression", <u>Gastroenterology</u> , Vol. 110, No. 2, (1996), pp. 375-382	
		UEDA, T., et al., "Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis", <u>J Gastroenterol</u> , Vol. 29, (1994), pp. 423-429	
		WIKSTROM, P., et al., "Transforming Growth Factor beta1 is Associated with	


EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin M.D., Kevin
Group Art Unit	1645
Examiner Name	Unknown

Sheet 3 of 3

Attorney Docket No: 675.002US1

TECH CENTER 1600/2900

JAN 28 2003

RECEIVED

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Angiogenesis, Metastasis, and Poor Clinical Outcome in Prostate Cancer", <u>The Prostate</u> , 37, (1998), pp. 19-29	
		WOLFF, J.M., et al., "Serum Concentrations of Transforming Growth Factor- $\beta$ 1 in Patients with Benign and Malignant Prostatic Diseases", <u>Anticancer Research</u> , Vol. 19, (1999), pp. 2657-2659	
		WOLFF, J.M., et al., "Transforming growth factor-beta 1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia", <u>Br. J. Urol.</u> , Vol. 81, abstract, (1998), 1 page	
		WUNDERLICH, H., et al., "Serum Transforming Growth Factor- $\beta$ 1 in Patients with Renal Cell Carcinoma", <u>The Journal of Urology</u> , Vol. 157, (May, 1997), pp. 1602-1603	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached